We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
Semaglutide as an important medicine for managing combined heart, kidney, and metabolism problems
AI simplified
Abstract
Semaglutide may reduce major adverse cardiovascular events (MACE) by 26% in high cardiovascular-risk patients with type 2 diabetes.
- In type 2 diabetes, semaglutide improves glycemic control and slows chronic kidney disease progression.
- The SUSTAIN-6 trial indicated a 26% reduction in MACE among patients taking semaglutide at doses of 0.5 or 1.0 mg weekly.
- The FLOW trial found a 24% reduction in major kidney disease events with 1.0 mg semaglutide in individuals with type 2 diabetes and chronic kidney disease.
- The SELECT trial demonstrated a 20% reduction in MACE with weekly 2.4 mg semaglutide in overweight or obese individuals with preexisting cardiovascular disease.
- Semaglutide also alleviates heart failure symptoms and reduces hospitalizations in obese individuals, regardless of type 2 diabetes status.
AI simplified
Key numbers
26%
MACE Reduction
Reduction in major adverse cardiovascular events in patients with T2D.
24%
Kidney Disease Event Reduction
Reduction in major kidney disease events in T2D patients with CKD.
20%
MACE Reduction in Obese Patients
Reduction in major adverse cardiovascular events in overweight or obese individuals with preexisting CV disease.